Details:
Evaxion Biotech is developing tailored cancer vaccines by targeting a novel category of AI-identified tumor antigens, named Endogenous Retroviruses (ERVs) to provide treatment solutions to cancer patients who are usually unresponsive to cancer immunotherapy.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 24, 2024
Details:
uTREAT® is new type of targeted radiation therapy, targeting and irradiating the cancer cells and almost not healthy tissue. By injecting a substance that seeks all cancer cells, this offers a personalised and tailored therapy to each patient.
Lead Product(s): Peptide-based Radioligand Therapy
Therapeutic Area: Oncology Product Name: uTREAT
Highest Development Status: Preclinical Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 07, 2023
Details:
Adcendo intends to use the proceeds from the financing to initiate a broad clinical development program for uPARAP Antibody Drug Conjugate in Sarcoma and is also planning to advance the development of its 2nd ADC pipeline asset.
Lead Product(s): Antibody Drug Conjugate
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Pontifax Venture Capital
Deal Size: $89.5 million Upfront Cash: Undisclosed
Deal Type: Series A Financing April 04, 2023
Details:
Debiopharm obtains global rights from Novo Nordisk for the development of FT-3171, a small molecule (ubiquitin-specific protease 1) USP1 inhibitor program targeting a novel DNA damage repair (DDR) pathway.
Lead Product(s): FT-3171
Therapeutic Area: Oncology Product Name: FT-3171
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Debiopharm
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition March 02, 2023
Details:
The preclinical data demonstrate that tumor neoantigens identified by Evaxion’s AI platform, PIONEER, drive a strong immune response and lead to complete inhibition of tumor growth in a preclinical model.
Lead Product(s): mRNA-based Vaccine
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Vaccine
Partner/Sponsor/Collaborator: Pantherna Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 08, 2023
Details:
Under the terms of the agreement, the companies will equally share the development costs and potential future profit deriving from GEN1053/BNT313. GEN1053/BNT313 is a CD27 antibody based on the HexaBody® technology, specifically engineered to form an antibody hexamer.
Lead Product(s): BNT313
Therapeutic Area: Oncology Product Name: GEN1053
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: BioNTech
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Expanded Collaboration August 05, 2022
Details:
In vitro data demonstrated selective binding and activation of IL-2 β/γ receptor, associated with reduced IL-2 α receptor binding.
Lead Product(s): TransCon IL-2 β/γ
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2020